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SIGNIFICANCE
Desmoplakin (DSP) and Desmoglein 1 (DSG1) gene chan-
ges result in skin barrier defects leading to widespread red 
scaly rash, skin thickening on the palms and soles and va-
riable other features. We report here a patient with a no-
vel DSP gene change, novel features of brain lesions and 
severe viral infections, and a favourable response to treat-
ment with ustekinumab. Woolly hair, nail abnormalities and 
heart problems characterize patients with DSP gene chan-
ges, while elevated serum IgE levels and food allergies are 
frequent in patients with DSG1 gene changes. Clinicians 
should be aware of the diverse consequences of DSP and 
DSG1 gene abnormalities. 
Desmoplakin (DSP) and Desmoglein 1 (DSG1) variants 
result in skin barrier defects leading to erythroderma, 
palmoplantar keratoderma and variable other features. 
Some DSG1 variant carriers present with SAM syndro-
me (Severe dermatitis, multiple Allergies, Metabolic 
wasting) and a SAM-like phenotype has been reported 
in 4 subjects with different heterozygous DSP variants. 
We report here a patient with a novel DSP spectrin re-
gion (SR) 6 variant c.1756C>T, p.(His586Tyr), novel 
features of brain lesions and severe recurrent muco-
cutaneous herpes simplex virus infections, with a fa-
vourable response to ustekinumab. Through a review 
of reported cases of heterozygous variants in DSP SR6 
(n = 15) and homozygous or compound heterozygous 
variants in DSG1 (n = 12) and SAM-like phenotype, we 
highlight phenotypic variability. Woolly hair, nail ab-
normalities and cardiomyopathy characterize patients 
with DSP variants, while elevated immunoglobulin E 
and food allergies are frequent in patients with DSG1 
variants. Clinicians should be aware of the diverse ma-
nifestations of desmosomopathies.
Key words: desmoglein; desmoplakin; metabolic wasting; SAM 
syndrome; severe dermatitis.
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Desmoplakin and desmogleins form the integral parts of desmosomes, which are adhesive intercellular 
junctions crucial in tissues prone to mechanical stress 
(e.g. skin, heart, gastrointestinal mucosa) (1). Desmo-
somal proteins play a role in cell signalling and skin 
barrier function.
Desmoglein 1 (DSG1) and Desmoplakin (DSP) encode 
critical components of desmosomes, and pathogenic 
variants in both genes have been implicated in inflam-
matory skin disorders. DSG1 variants have been reported 
recently in patients with designated SAM syndrome 
(Severe dermatitis, multiple Allergies and Metabolic 
wasting) with an extremely variable phenotype consis-
ting of severe erythrodermic dermatitis, failure to thrive 
(FTT), recurrent infections, metabolic wasting, multiple 
allergies, increased immunoglobulin (Ig) E levels and 
eosinophilia (2–7). 
Two patients with different heterozygous DSP vari-
ants were reported to have a SAM-like phenotype (8, 
9). Autosomal dominant DSP variants within the same 
spectrin 6 (SR6) region also cause erythrokeratoderma 
and cardiomyopathy (10), and palmoplantar keratoderma 
(PPK) with woolly hair, cardiomyopathy and arrhythmias 
(11). Recently, 2 additional patients with heterozygous 
DSP SR6 variants have been reported to display SAM 
syndrome, together with ectodermal dysplasia and car-
diomyopathy (coined SAMEC syndrome) (12). 
The lack of epithelial barrier proteins commonly seems 
to lead to immunological dysregulation. Impaired epit-
helial barrier function enhances Th2 responses and leads 
to chronic activation of the immune system (13). DSG1 
deficiency results in increased expression of various 
genes encoding cytokines involved in allergic manifes-
tations, such as IL5 and TNF (2). In SAMEC, DSG1 
was linked to an inability to retain ERBB2-interacting 
protein (ERBIN) at the cell membrane, probably hampe-
ring NF-κB pathway inhibition and promoting epithelial 
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inflammation (12). Heterozygous DSP variants associate 
with abnormally high levels of proinflammatory cytoki-
nes (interleukin (IL) 6, IL-8, and IL-1β), NF-kB target 
gene products, and thymic stromal lymphoprotein in the 
keratinocytes (12). The dysregulated epidermal immune 
environment triggers early-onset allergic manifestations 
beyond the skin, including asthma and allergic rhino-
conjunctivitis, as well as eosinophilic oesophagitis and 
colitis similar to patients with Netherton syndrome (14). 
Desmoplakin anchors intermediate filaments to desmo-
somal plaques and is expressed at high levels in the skin 
and heart muscle, and at medium levels in bronchi and 
oesophagus (15). Importantly, individuals with DSP and 
other desmosomal gene variants are at risk of developing 
cardiomyopathy and lethal arrhythmias, typically at the 
age of 3–12 years (16), warranting continuous cardiac 
follow-up.
We report here a patient with a novel DSP SR6 re-
gion variant (c.1756C>T, p.His586Tyr), presenting with 
erythro dermic ichthyosis, severe FTT, oesophagitis, 
recurrent infections, and novel features, such as severe 
recurrent mucocutaneous herpes simplex virus (HSV) 
infections, pyogenic granuloma on the tongue, gastritis 
and brain lesions, further diversifying the DSP-related 
phenotype. We also reviewed all reported patients with 
heterozygous variants in DSP SR6 and with homozygous 
or compound heterozygous variants in DSG1 and SAM/
SAMEC-like phenotype, in order to delineate variable 
and overlapping clinical features.
METHODS
Written informed consent was obtained from the patient’s parents, 
including permission to publish the photographs.
The immunological assessment, skin histopathology and immu-
nohistochemistry, hair analysis, oesophagus and gastric biopsies, 
whole-exome sequencing and variant analysis, protein modelling, 
as well as literature search and statistical analyses, are described 
in detail in Appendix S11.
RESULTS
Case description
Our patient is the first child of non-consanguineous 
parents of Arab descent, born at term with normal 
weight and length. At 2 weeks of age, he developed an 
intertriginous seborrhoeic eczema-like dermatitis (Fig. 
1A). A pustular eruption emerged at age 1.5 months and 
rapidly evolved into a severely pruritic and seemingly 
painful ichthyosiform erythroderma (Fig. 1B). His hair 
was normal at birth, but total alopecia developed at 3 
months. His nails were abnormally thin and soft.
He had had relapsing Staphylococcus aureus skin in-
fections, Candida albicans thrush, recurrent enterococcal 
and staphylococcal sepsis since the age of 4 months. At 
5 months, he developed severe and relapsing protracted 
HSV-1 stomatitis with extensive mucocutaneous invol-
vement (Fig. 1C). Extensive infectious, immunological 
and metabolic evaluations were mostly normal and did 
not suggest any specific immunodeficiency syndrome. 
From age 4 months onwards, he developed difficulties 
with swallowing and progressive FTT. These necessitated 
percutaneous gastrostomy and initiation of amino acid-
based formula feeding. Cow milk protein intolerance was 
diagnosed at 7 months by an in-hospital oral provocation 
challenge and manifested as profuse vomiting, diarrhoea 
and inconsolable crying within hours of administration 
of standard formula. At 6 months, his serum IgE levels 
increased up to 958 kU/l (normal < 70 kU/l), but then 
gradually returned to near normal value (102 kU/l). 
Eosinophil counts remained normal. In the ImmunoCAP 
specific IgE assay against 112 allergens, only a low-level 
reactivity (0.7 ISU, normal > 0.3 ISU) to prohevein rHev 
b 6.01 was detected at 9 months, but at 11 months po-
sitivity to peanut (0.37 kU/l) and egg-white (1.03 kU/l) 
appeared. Profound fluid balance disturbances with hypo- 
and hypernatremia and rapid dehydration or generalized 
oedema occurred during erythrodermic flares. Arrhythmia 
or cardiac abnormalities have, so far, not been detected.
Upper gastrointestinal tract endoscopy was normal 
at 4 months, but revealed lymphocyte and plasmablast 
mucosal infiltrates in the stomach at 7 months. After 
several courses of proton pump inhibitors, his gastric 
histology normalized at 2 years of age. However, he then 
exhibited mild oesophagitis with some intraepithelial 
eosinophils, not numerous enough to fulfil the criteria 
for eosinophilic oesophagitis.
Motor development was delayed from the age of 4 
months. Brain magnetic resonance imaging (MRI) at 4 
months showed symmetrical diffusion restriction in the 
superior cerebellar peduncles and decussation. Also, 
red nuclei in mesencephalon, subthalamic region, globi 
pallidi and optic radiation were involved (Fig. S11). Re-
peated MRI a month later showed no progression of these 
changes. His motor development progresses, but remains 
delayed, with no independent walking at 2 years of age.
At 6 months he developed a firm papular lesion 2.0 
cm in diameter on his tongue (Fig. 1D), which resolved 
spontaneously over months. Biopsy of the lesion re-
vealed a pyogenic granuloma. HSV-1, cytomegalovirus 
and human papillomavirus (HPV) 11 were found in the 
lesion by nucleic acid assay, while other viral, bacterial, 
mycobacterial and fungal investigations were negative. 
The patient’s skin was treated with basic emollients 
and courses of topical mild potency corticosteroids. 
McAleer et al. (8) reported topical tacrolimus, systemic 
antibiotics, intravenous immunoglobulin (IVIG) therapy 
and systemic acitretin to be effective in their patient with 
a DSP variant. At 5 months, IVIG therapy for recurrent 
sepsis was commenced. He has had no bacterial infec-1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3203
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tions since, while recurrent mucocutaneous HSV-1 flares 
have necessitated continuous acyclovir prophylaxis. 
IVIG substitution was stopped at 20 months. Acitretin 
was started at a low dose of 0.25 mg/kg every other day 
at 7.5 months (8). Acitretin slightly alleviated scaling, 
erythema and itch and induced hair regrowth (Fig. 1E). 
Due to constant vomiting, acitretin was stopped at 14 
months, followed by no significant change in his skin 
condition nor vomiting. His first tooth erupted at 10 
months and his teeth have been normal. At 18 months, 
he developed ichthyotic erythroderma (Fig. 1F–H), and, 
additionally, he has developed mild PPK and onycho-
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Fig. 1. Clinical features of the reported patient. (A) An intertriginous seborrhoeic like eczema at 2 weeks of age (B) evolved into a ichthyosiform 
erythroderma at 1.5 months. (C) Severe and relapsing HSV-1 stomatitis at 5 months and (D) a pyogenic granuloma on the tongue at 6 months. (E) 
Slight alleviation of scaling and erythema and hair regrowth after initiation of acitretin therapy at 7 months. (F) Ichthyotic erythroderma at 18 months 
with the development of (G) slight palmoplantar keratoderma (PPK) and (H) onychodystrophy. (I–K) Response to ustekinumab treatment at 25 months 
included hair regrowth and alleviation of skin scaling and PPK. DSP mutation leads to decreased levels of DSP, DSG1 and KRT10. (L) Skin tissue of a 
normal control shows prominent DSP antibody staining throughout the epidermis in suprabasal cells, while in the patient (M) only a weak staining is seen 
in the upper epidermis. DSG1 is distinct intercellularly in (N) healthy skin, but almost totally lost (O) in the patient. KRT10 stains intensely in (P) the 
suprabasal healthy skin, but is weak in the patient’s upper epidermis and (Q) diminished in the suprabasal layers. Electron microscopy of the patient’s 
skin biopsy samples shows the loss of intercellular cohesiveness, especially (R) suprabasally and decreased numbers of desmosomes and tonofilaments, 
as well as (S) the absence of perinuclear tonofilaments. Written permission from the parent.
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dystrophy. His growth has improved substantially due 
to optimized enteral nutrition. 
Since 2 patients with DSP variants were reported to 
benefit from ustekinumab therapy, with reduction in 
itching and in dermatitis severity and improvement in 
hair thickness (9), we initiated ustekinumab treatment 
at 22 months in our patient. Ustekinumab (0.75 mg/kg) 
was given initially at 4 weeks and from then on every 12 
weeks, leading to alleviation of pruritus, skin scaling and 
PPK, as well as better hair growth after the first 2 injec-
tions (Fig. 1I–K). Oral intake also improved significantly, 
and gastrostomy use could be discontinued. Along with 
clinical improvement, serum levels of IL-17A, IL-17F 
and IL-23 decreased strikingly, whereas concentrations 
of IL-12p70 somewhat increased, albeit at very low levels 
(< 1 pg/ml) (Fig. S21).
Skin biopsy findings. Skin biopsy from the pustular erup-
tion at 1.5 months showed eczema with a neutrophilic 
infiltrate and microabscesses. Biopsy at 3 months from 
the erythrodermic skin revealed a psoriasiform reaction 
pattern with a dense ichthyosiform stratum corneum and 
neutrophilic infiltrates in the epidermis and upper dermis. 
Filaggrin immunostaining was reduced in the first and 
absent in the second biopsy, suggesting ichthyosis, while 
LEKTI immunostaining was normal in both biopsies 
(data not shown). Hair morphology was normal. Immu-
nohistochemistry demonstrated significant decrease in 
desmoplakin, desmoglein 1 and keratin 10 (Fig. 1L–Q). 
Skin electron microscopy revealed decreased numbers of 
desmosomes and tonofilaments, and perinuclear tonofila-
ments were absent. The loss of intercellular cohesiveness 
was especially prominent suprabasally (Fig. 1R–S). 
Genetic work-up. Ichthyosis and primary immuno-
deficiency gene panels (Blueprint Genetics, helsinki, 
Finland) detected no pathogenic variants. Clinical whole-
exome sequencing was performed with median sequen-
cing coverage of 132× and 99.1% of target regions were 
covered with at least 20 reads. Analysis of whole-exome 
sequence variants revealed a novel heterozygous mis-
sense variant in the DSP gene: c.1756C>T, p.(His586Tyr) 
(NM_004415.2), confirmed with bidirectional Sanger 
sequencing. Based on Sanger sequencing analysis, the 
parents were not carriers, thus the variant was de novo 
in the patient. This variant has not been reported in the 
Exome Aggregation Consortium (ExAC) database or 
Genome Aggregation Database (gnomAD). The variant 
is predicted deleterious by in silico tools SIFT and Mu-
tationTaster and benign by PolyPhen, the CADD score 
(PHRED-like scaled C-score) is 24.3, suggesting that the 
amino acid change is deleterious. The His586 residue 
is located within one of the spectrin repeat domains, 
SR6, which is a hotspot for dominant missense variants 
causing cutaneous disease (10). Historical patient with a 
similar phenotype carried a de novo missense variant in 
the same amino acid residue p.(His586Pro) (8). Protein 
modelling with the template-based protein structure 
tools RaptorX (17) and Swiss-model (18) did not predict 
alterations in the protein structure. However, histidine 
is an amino acid with unique chemical properties not 
particularly well substituted with any other amino acid. 
Clinical whole-exome sequencing also identified a 
variant of uncertain significance, a novel heterozygous 
in-frame deletion c.11361_11387del, p.(Asp3788_Thr-
3796del) (NM_001376.4) in DYNC1H1, which encodes 
the heavy chain of cytoplasmic dynein 1 that acts a motor 
involved in trafficking of vesicles and organelles along 
microtubule. The variant deletes 9 highly conserved 
amino acid residues in the motor domain of DYNC1H1 
(19). Sanger sequencing of both parents revealed that the 
variant has occurred de novo in the patient.
Literature review on DSP and DSG1 variants and 
phenotype
The clinical and laboratory characteristics of the patients 
were compared with heterozygous variants in DSP SR6 
and with homozygous or compound heterozygous va-
riants in DSG1 and SAM-like phenotype (Table I and 
Fig. 2). SR6 region dominant DSP variants have been 
reported in 15 patients, with clinical features ranging 
from a constellation of PPK, woolly hair and arrhyth-
mogenic cardiomyopathy at one end of the spectrum 
(patients 7–13) to a SAM-like disease with erythroderma, 
ichthyosis, hypotrichosis, recurrent infections, FTT 
and gastrointestinal manifestations (patients 1–3, 14) 
at the other end of the spectrum (Table I). Overlapping 
features of cardiomyopathy, erythroderma, ichthyosis, 
hypotrichosis, PPK and woolly hair have been reported 
in another 4 patients with DSP variants (patients 4–6, 
15, Table I). 
Overall, the shared clinical manifestations (DSP/
DSG1) are as follows: PPK (100%/92%), erythroderma 
(53%/67%), ichthyosis (53%/50%), FTT (40%/33%), re-
current infections (20%/33%), gastrointestinal problems 
(27%/17%) and developmental delay (20%/25%) (Fig. 
2). Otherwise, clinical features varied considerably. Sub-
jects with DSG1 variants do not manifest eosinophilia, 
pustulosis, dental and ophthalmic abnormalities, hoarse 
voice, cardiomyopathy or arrhythmias. Woolly hair and 
nail abnormalities were more common in patients with 
DSP variants (14/15 vs. 4/12, p = 0.003 and 11/15 vs. 
1/12, p = 0.001, respectively), while elevated IgE and 
food allergies were observed more frequently in patients 
with DSG1 variants (10/12 vs. 3/15, p = 0.002 and 8/12 
vs. 3/15, p = 0.022, respectively). 
DISCUSSION
We report here a patient with a novel DSP variant 
c.1756C>T, p.His586Tyr and severe erythrodermic 
ichthyosis, resembling, but distinct from, SAM, with 
previously undescribed features of severe recurrent 
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mucocutaneous HSV-1 infection, oral pyogenic granu-
loma, gastritis and brain lesions. The patient was treated 
successfully with ustekinumab, targeting the IL-12 and 
IL-23 as well as downstream IL-17 pathways and adding 
to the previously reported favourable experience with this 
medication in another 2 patients with DSP SR6 variants 
(9). The current patient is thus the third case reported to 
benefit from ustekinumab therapy.
Patients with SAM present with chronic inflamma-
tion of the skin and gastrointestinal epithelium, leading 
to a dysregulated immune response (9, 12). Our patient 
showed lymphocytic and plasmablast infiltrates in the 
gastric mucosa. Coupled with swallowing difficulties 
and gradually progressing vomiting, as well as further 
development of mild oesophagitis, these may reflect des-
moplakin-related disruption of gastrointestinal mucosa or 
food intolerance. The severe reaction to cow’s milk was 
out of proportion to his serum IgE levels and resembled 
food protein-induced enterocolitis syndrome (23).
The aetiology of brain abnormalities in our patient 
remains unexplained, since DSP is not expressed in the 
central nervous system (The Human Protein Atlas; GTEx 
Portal) and since DSP variants have not been associated 
with brain tissue pathology. Therefore, factors such as 
undiagnosed perinatal hypoxia, severe FTT and drastic 
dysnatraemia may contribute. However, developmental 
delay has been reported in association with some DSP 
variants (Table I) and its link to desmosomal protein 
dysfunction warrants further study. Interestingly, our 
patient had a novel heterozygous de novo inframe dele-
tion p.(Asp3788_Thr3796del) in DYNC1H1, of which 
de novo variants have been reported in patients with 
malformations of cortical development and various other 
neurological disorders (24, 25). However, the contribu-
tion of the DYNC1H1 variant to aetiology of the observed 
symmetrical bilateral diffusion modality changes in our 
patient remains unknown.
The self-resolving tongue pyogenic granuloma in 
our patient was positive for multiple viral nucleic 
acids. Although HPV is a well-known cause of mouth 
papillomatous lesions, both HPV and CMV nucleic 
acids are frequently detected in oral cavities of healthy 
infants (26, 27). Instead, HSV-2 and HSV-1 have been 
reported to cause self-resolving pseudotumour on the 
tongue (28) and pyogenic granuloma (29), consistent 
with the preceding HSV-1 mucocutaneous infection 
in our patient. Also, mechanical stress from a recently 
introduced pacifier may have contributed to lesion 
formation (30).
IVIG therapy may have reduced the number of bacte-
rial infections in our patient, as well as in the first des-
cribed individual with SAM due to DSP variant, despite 
the normal pretreatment IgG levels in both. Also, IVIG 
has demonstrated efficacy in patients with Netherton 
syndrome (31). This may reflect the need for higher IgG 
levels in patients with epidermal barrier defects who 
lose protein continuously via inflamed skin. In addition, 
specific antibody deficiency has been described in some 
subjects with Netherton syndrome (32). In our patient, 
IgG levels decreased despite initiation of IVIG, but sta-
bilized after higher and more frequent IVIG dosing. The 
beneficial effects of IVIG therapy in our case may thus be 
explained by age-specific immature antibody production 
exacerbated by chronic protein loss via skin. Acitretin is 
Fig. 2. The prevalence of clinical features in 15 patients with DSP (black bars, Table I) and 12 patients with DSG1 (grey bars, references 2–7) 
variants.
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successfully used in the management of ichthyoses (33, 
34) and was also partially effective in our patient. 
Ustekinumab targets the disrupted balance of IL-23 /
Th17 pathway and has been efficient in controlling skin 
inflammation in 2 patients with DSP SR6 variants (9), 
as well as in our case. We provide novel data on the de-
crease in serum IL-17A and IL-17F levels after initiation 
of ustekinumab therapy, adding evidence of its biologic 
efficacy in patients with DSP mutations. The increase 
in IL-12p70 levels, although in levels below 1 pg/ml, 
during ustekinumab therapy may reflect a compensatory 
protective effect of IL-12 in skin inflammation (35). 
Follow-up studies are needed to test the efficacy, if any, 
of ustekinumab in preventing the development of car-
diomyopathy, a fatal complication seen in the majority 
of DSP SR6 variant patients (Table I).
Patients with SR6 DSP variants manifest a spectrum of 
clinical features, ranging from PPK and cardiomyopathy 
to SAM-like disease. We add severe HSV-1 infection, 
brain abnormalities and persistent gastrointestinal pro-
blems to the diversity of their phenotype. DSP variants 
should be included in the differential diagnosis of infants 
with ichthyosiform erythroderma, FTT, recurrent infec-
tions and these novel features, to allow rapid diagnosis 
and early therapy. Based on current literature, the clinical 
features in SAM, SAMEC and SAM-like phenotypes 
are highly variable. Clinicians caring for these patients 
should be familiar with the diverse manifestations of 
desmosomopathies, as well as the importance of early 
genetic diagnosis, given that only patients with DSP SR6, 
not DSG1 variants, are at inevitable risk of developing 
cardiomyopathy. Further studies on the mechanisms of 
immune dysregulation in patients with DSG1 and DSP 
variants would provide background for novel targeted 
therapies, such as immunosuppressants or immunomo-
dulators.
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